CG-0416 / CureGene Pharmaceuticals - LARVOL DELTA

CureGene Unveils Groundbreaking Preclinical Data for CG-0416, a Novel Oral Non-GLP-1 Therapy, at Obesity Week 2025 (PRNewswire) - "Data presented revealed that in diet-induced obese (DIO) mouse models, CG-0416 monotherapy demonstrated superior 'high-quality weight loss'. While achieving weight reduction comparable to semaglutide..., approximately 95% of the weight loss with CG-0416 came from fat mass reduction, with minimal muscle loss. In contrast, about one-third of semaglutide-induced weight loss was attributed to lean mass reduction."

Preclinical • Obesity